TNG260 is a first-in-class, highly selective CoREST complex inhibitor currently being evaluated with pembrolizumab in the dose expansion phase of the TNG260 Phase 1/2 trial. The trial is currently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback